Cargando…
Using continuous data on tumour measurements to improve inference in phase II cancer studies
In phase II cancer trials, tumour response is either the primary or an important secondary endpoint. Tumour response is a binary composite endpoint determined, according to the Response Evaluation Criteria in Solid Tumors, by (1) whether the percentage change in tumour size is greater than a prescri...
Autores principales: | Wason, James MS, Seaman, Shaun R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282550/ https://www.ncbi.nlm.nih.gov/pubmed/23776143 http://dx.doi.org/10.1002/sim.5867 |
Ejemplares similares
-
Using continuous data on tumour measurements to improve inference in phase II cancer studies
por: Wason, James, et al.
Publicado: (2013) -
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien‐Ju, et al.
Publicado: (2017) -
The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected
por: Wason, James MS, et al.
Publicado: (2015) -
Improving phase ii oncology trial using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien-Ju, et al.
Publicado: (2015) -
Minimizing the Maximum Expected Sample Size in Two-Stage Phase II Clinical Trials with Continuous Outcomes
por: Wason, James M. S., et al.
Publicado: (2012)